VCEL

Vericel is a genuinely good business priced like a perfect one. The operating record is excellent: revenue has compounded from $153M (2021) to $276M (FY2025), a fifth straight year of mid-teens-plus growth (+16.5%), while the company crossed from chronic losses into its second consecutive profitable year (net income $16.5M, +59.4%; diluted EPS $0.32, +60%). Gross margin is a software-like 74.4% on cell therapies (MACI cartilage repair, Epicel, NexoBrid burns), and operating income more than doubled to $11.0M, evidence that scale is finally translating into operating leverage. The balance sheet is pristine — $100M cash plus, per the MD&A, $37.4M short-term and $61.4M long-term investments, zero drawn on the $150M JPMorgan revolver, liabilities/equity of just 0.38x, and $51.9M of operating cash flow. There is no solvency or dilution pressure here (shares up only 1.6%).

The problem is the price, not the company. At $45.07 the stock trades at 140.8x trailing EPS and 8.3x sales, yet the underlying engine still earns only a 4.0% operating margin, a 6.0% net margin and a 4.7% ROE — the lofty P/E is a function of thin (if rapidly rising) earnings, not of franchise-level returns on capital. The accumulated deficit of -$376M is a reminder of how long it took to reach profitability, and the company itself warns it 'may not achieve consistent profitability for some time or at all' and expects 'significant quarterly and annual fluctuations.' Capex stepped down sharply (-57.5%) as the Burlington manufacturing buildout winds down, which should aid free cash flow, but most of the optimistic margin-expansion and NexoBrid-ramp story already appears embedded in the multiple.